# Poly(lactic acid)-Based Electrospun Fibrous Structures for Biomedical Applications
## 8 Biomedical Applications of PLA-Based Nanofibrous Structures
### Wound Healing
\begin{table}
\begin{tabular}{c c c c c c c c} \hline \multirow{2}{*}{**Polymers and Blends**} & **Molecular Weight** & \multirow{2}{*}{**Solvent (s)**} & \multirow{2}{*}{**Active Compound**} & \multicolumn{2}{c}{**Average Fiber**} & \multirow{2}{*}{**Type of Cell**} & \multirow{2}{*}{**Reference**} \\  & **g\(\cdot\)mol\({}^{-1}\)** & & & & & **Dianetere** & **(mm)** & \\ \hline \multirow{3}{*}{PLA} & \multirow{3}{*}{Mw = 124,900} & \multirow{3}{*}{chlorororm: DMF} & \multicolumn{3}{c}{Decamethasone} & \multirow{3}{*}{\(311\pm 74\)} & \multirow{3}{*}{Emulsion} & \multirow{3}{*}{[2]} \\  & & (80:20 \(\circ\)/\(\pi\)) & & & & & \\ \cline{3-5}  & & & (14 \(\omega\)/\(\pi\)/\(\pi\)) & & & & \\ \hline PLLA & \multirow{3}{*}{Mn = 200,000} & DMF: DCM (3.7 \(\circ\)/\(\pi\)) & Curcumin (1 \(\omega\)/\(\pi\)/\(\pi\)) & \multirow{3}{*}{\(380\pm 113\)} & Human adult dermal fibroblasts (HDFA) & Emulsion & [74] \\ \cline{3-5}  & & & (1 \(\omega\)/\(\pi\)/\(\pi\)) & & & \\ \hline PLLA & \multirow{3}{*}{Mn = 200,000} & chloroform: DM/Ac & Curcumin & \multirow{3}{*}{\(943\pm 383\)} & \multirow{3}{*}{\(5\)C\({}_{12}\)} & Emulsion & \multirow{3}{*}{[75]} \\  & & (80:20 \(\circ\)/\(\pi\)) & & & & \\ \cline{3-5}  & & & (12.5 \(\circ\)/\(\pi\)) & & & & \\ \hline PLA/PEG (20 wt5) & \multirow{3}{*}{Mn = 146,000} & chloroform: acetone & Curcumin & \multirow{3}{*}{\(430\)} & \multirow{3}{*}{\(430\)} & \multirow{3}{*}{\(\text{MC-63 cells}\)} & \multirow{3}{*}{\(\text{Bend}\)} \\  & & & (21 \(\circ\)/\(\pi\)) & & & & \\ \cline{3-5}  & & & (10 wt5) & & & & \\ \hline PLA & \multirow{3}{*}{Mw = 90 000} & DM/AC/acetone (1.1), & Em  
\begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline
**Polymers and Blends** & **Molecular Weight** & **Solvent (s)** & **Active Compound** & **Average Fiber** & **Type of Cell** & **Reference** \\  & **g.mol\({}^{-1}\)** & & & & & **(nm)** & \\ \hline PLLA & Mw = 217,000 to & Chloroform/DMF 9-1 & & & & & \\ PEG, & 255,000, & & ethanol/distilled water & Hypericum & PLLA = 186 \(\pm\) 68 & Normal human dermal & Blend & [82] \\ Chitosan (CS) & Mw = 100,000 & 82 (\(\gamma\)/s), & & & & & \\ MW = 5000-190,000 & 14/s acetic acid (\(\gamma\)/s) & & & & & \\ \hline PLA & 1,000,000 & DCM/DMF & & & & & \\ (DG-DL400), & 21 (\(\gamma\)/s) & & & & & \\ \hline PLA (2.075) & & DCM/DMSO & & & & & \\  & & 41 (\(\gamma\)/s) & & & & \\ \hline PLA & Mw = 70,000 & DMF/ chloroform (1:3) & & & & & \\ (20 wt) & 478.31 \(\pm\) 167.61 & HDF \& HEK from & & & \\ adult human skin & & & & & & \\ \hline PLLA-CLJ/PDEGMA & & & & & & & \\ 1:1 & & HFIP & Ciprofloxacin/loxacin & & & \\  & & & & & & \\  & & & & & & \\ \hline PLA/polyurethane & Mw = 100,000 & Acetone: DMA & Doxorubicin (DOO) & & & & \\  & & & Plasmid DNA & & & \\  & & & & & & \\ \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**Polymers and Blends** & **Molecular Weight** & **Solvent (s)** & **Active Compound** & **Average Fiber** & **Type of Cell** & **Reference** \\  & **g.mol-1** & & & **(mm)** & & \\ \hline PLLA as shell, & PLLA, & Chloroform for PLA & & 1299 cells, Twenty-four & Coaxial & \\ poly(glycerol sebacate) & (Mn = 200 kDa) & DCM and DMF (\(\varepsilon v=\) 3:1) for PCS & & & & \\  & & & & & \\ \hline PLLA as core & & & & & & \\  & & & & & \\  & & & & & \\  & & & & & \\  & & & & & \\ \hline PLLA as shell, PVA as & Mn PLA = 125 \(\times\) 10\({}^{2}\), & DCM/ DMF (1.9 ratio) & Connective tissue growth factor (CTG) & 260 \(\pm\) 140 & Extantocytes and endothelial cells & Covaxial & [91] \\  & & & & & \\ \hline \hline \end{tabular}
\end{table} 
Table 1: _Cont._In most of these studies, bioactive PLA-based electrospun membranes have been developed as wound healing products with multifunctional properties, in which electrospun fibers are carrying different drugs; for example, [PERSON] et al., demonstrated that PLA electrospun membranes are promising wound dressings with the ability of sustainable released drug delivery [2].